# PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy

Study · id `cardio:ct-nct06915792` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06915792](<https://clinicaltrials.gov/study/NCT06915792>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06915792

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT06915792. Randomized; no masking; primary purpose treatment. Start 2025-06-01 (actual); primary completion 2027-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT06915792, source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)
- Started: 2025-06-01 (actual) (ClinicalTrials.gov record NCT06915792, source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)
- Primary completion: 2027-07-31 (anticipated) (ClinicalTrials.gov record NCT06915792, source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)
- Completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT06915792, source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06915792, source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06915792-2026-06-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: PEACE Trial: Postpartum Evaluation of Antihypertensive Cessation and Efficacy
- Acronym: PEACE
- Condition: Postpartum Hypertension (PPHT)
- Intervention (Drug): Labetalol
- Intervention (Drug): Nifedipine
- Lead sponsor: University of California, Los Angeles
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Nifedipine (`cardio:nifedipine`)
- Registry lists this organization as the lead sponsor: University of California, Los Angeles (`cardio:org-university-of-california-los-angeles`)

## Provenance

Content hash: 605af11a1395f842d7432465c142a57a6b7f0f2c0471618f3238dd785765fbb1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
